VRDN

AI Memo

Viridian Therapeutics

As of 2026-09-30/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

VRDN-008 phase 1 data and TSHR IND • 2026-12-31

Base target: $23 / p=50% prob

Biggest risk

Early launch indicators may not translate into durable sales amid payer friction and TEPEZZA competition. Q2 SG&A rose to $55.0 million and net loss reached $127.1 million as commercial infrastructure expanded; development or filing delays would extend the period of losses. [#PR-EARNINGS-2026-08-06]

Invalidation

Break below $11 or thesis failure.

What would change my mind?

Lumvoa converts early physician interest into reimbursed treatment, while 2026 pipeline milestones and a timely elegrobart BLA broaden Viridian's TED opportunity. The company reported $981.5 million of cash, equivalents and marketable securities at June 30, 2026. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-30

Base target

$23

p=50%

Bull target

$34

p=25%

Bear target

$11

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Lumvoa launch uptake and payer access
Elegrobart BLA submission
Lumvoa converts early physician interest into reimbursed treatment, while 2026 pipeline milestones and a timely elegrobart BLA broaden Viridian's TED opportunity.

BearKey bullets

Amgen's established TEPEZZA franchise and subcutaneous program may constrain differentiation.
Amgen company release
Commercial spending, continued net losses and financing-related dilution or debt obligations could pressure valuation.

WatchKey bullets

VRDN-008 phase 1 data and TSHR IND

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $23 (p=50%)

Target spread vs base: +48% / -52%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $23 (p=50%)Bear Target: $11 (p=25%)

Commentary

Company-source tone is constructive after approval and the Q2 launch update, but the packet does not establish September sales, analyst revisions, a post-result price reaction, or reliable social, options, short-interest or employee-sentiment readings. The zero-valued sentiment fields denote unavailable data, not measured neutral readings. The positive case remains execution-dependent. [#SEC-8K-2026-08-06]

As of 2026-09-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Lumvoa launch uptake and payer access
Elegrobart BLA submission

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$23 / p=50% prob

Bear Target (Scenario probability)

$11 / p=25% prob

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
VRDN-008 phase 1 data and TSHR IND
Viridian expects VRDN-008 healthy-volunteer data in the second half of 2026 and anticipates a TSHR investigational new drug submission in Q4. Both remain development milestones, not demonstrated clinical efficacy. [#PR-EARNINGS-2026-08-06] [#SEC-8K-2026-08-06]
Prob 55.00% • Move 10.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Lumvoa launch uptake and payer access
2026-12-31
FDA-approved Lumvoa launched in June. Viridian reported first doses in July, engagement with 95% of 2,000 core prescribers, and payer-coverage efforts on track. Prescription conversion, reimbursement and repeat demand—not early engagement alone—will test the launch thesis. [#8-K-2026-08-06] [#SEC-8K-2026-08-06]
Prob 60% • Move 12% • Priced-in 45%

Long-term Catalysts

Months to a year

Elegrobart BLA submission
2027-03-31
Following positive REVEAL-1 and REVEAL-2 topline results, Viridian targets a Q1 2027 BLA submission for subcutaneous elegrobart. Filing readiness and subsequent FDA review remain execution risks. [#8-K-2026-08-06] [#SEC-8K-2026-08-06]
Prob 70% • Move 18% • Priced-in 40%

Risks

Amgen's established TEPEZZA franchise and subcutaneous program may constrain differentiation. Amgen company release
Commercial spending, continued net losses and financing-related dilution or debt obligations could pressure valuation. [#PR-EARNINGS-2026-08-06]
Elegrobart BLA timing, regulatory review and autoinjector execution could slip. [#SEC-8K-2026-08-06]
Lumvoa payer coverage, treatment starts and sustained revenue remain unproven beyond early launch indicators. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
AMGN	Direct TED commercial competitor through TEPEZZA, including a subcutaneous program; Amgen's much larger scale makes its equity valuation a poor direct multiple comparison. Amgen company release
ADMA	Similar-market-cap commercial biologics reference from the packet, but not a TED competitor; therapeutic and business-model differences limit valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-30

Loading AI feed…

Symbol

Summary

AMGN

Direct TED commercial competitor through TEPEZZA, including a subcutaneous program; Amgen's much larger scale makes its equity valuation a poor direct multiple comparison. Amgen company release

ADMA

Similar-market-cap commercial biologics reference from the packet, but not a TED competitor; therapeutic and business-model differences limit valuation comparability.